303 related articles for article (PubMed ID: 31854243)
1. Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure.
Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Murohara T; Ajioka M
Ther Adv Cardiovasc Dis; 2019; 13():1753944719894509. PubMed ID: 31854243
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
3. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
4. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
[TBL] [Abstract][Full Text] [Related]
5. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
Katsiki N; Triposkiadis F
Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
[No Abstract] [Full Text] [Related]
6. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
[TBL] [Abstract][Full Text] [Related]
7. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
[TBL] [Abstract][Full Text] [Related]
8. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
9. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
[TBL] [Abstract][Full Text] [Related]
10. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
Feng X; Gu Q; Gao G; Yuan L; Li Q; Zhang Y
Ann Endocrinol (Paris); 2020 Oct; 81(5):476-481. PubMed ID: 32822653
[TBL] [Abstract][Full Text] [Related]
11. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study.
Gamaza-Chulián S; Díaz-Retamino E; González-Testón F; Gaitero JC; Castillo MJ; Alfaro R; Rodríguez E; González-Caballero E; Martín-Santana A
BMC Cardiovasc Disord; 2021 Sep; 21(1):456. PubMed ID: 34548011
[TBL] [Abstract][Full Text] [Related]
12. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
Genuardi MV; Mather PJ
Ther Adv Cardiovasc Dis; 2021; 15():17539447211002678. PubMed ID: 33779401
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
[TBL] [Abstract][Full Text] [Related]
14. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care.
Tanaka A; Node K
Cardiovasc Diabetol; 2020 Sep; 19(1):132. PubMed ID: 32878601
[TBL] [Abstract][Full Text] [Related]
15. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
[TBL] [Abstract][Full Text] [Related]
16. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
17. How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?
Tanaka A; Node K
Cardiovasc Diabetol; 2020 Dec; 19(1):206. PubMed ID: 33287812
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
[TBL] [Abstract][Full Text] [Related]
19. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.
Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
Cardiovasc Diabetol; 2022 Aug; 21(1):157. PubMed ID: 35964039
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]